Stockscreener 앱 받기
2.745
1.96%
-0.055
시장 영업 전:
2.75
0.005
+0.18%
Entera Bio Ltd 주식(ENTX)의 최신 뉴스
Form PRE 14A ENTERA BIO LTD. For: 27 September By Investing.com - Investing.com Canada
Entera Bio Initiated at Buy by Guggenheim - Moomoo
Guggenheim Initiates Entera Bio at Buy With $11 Price Target - marketscreener.com
Guggenheim initiates Entera Bio stock with buy rating on oral peptide platform - Investing.com India
After raising about $275 million, Entera Bio (ENTX) asks shareholders to expand its share incentive plan. - Stock Titan
Entera Bio Receives New Overweight Rating From Cantor Fitzgerald (NASDAQ: ENTX) - TipRanks
Entera Bio Ltd. (ENTX) Initiated Overweight by Cantor; DCF Target $12.58 - TradingView
Entera Receives $9 Price Target And New 'Outperform' Rating From Leerink Partners (NASDAQ: ENTX) - Menafn
Entera Receives $9 Price Target and New ‘Outperform’ Rating From Leerink Partners (NASDAQ: ENTX) - TipRanks
Leerink Partners Initiates Entera Bio(ENTX.US) With Buy Rating, Announces Target Price $9 - Moomoo
Entera Bio Ltd. (NASDAQ:ENTX) Initiated at Outperform by Leerink With $9 Target - TradingView
Entera Receives $9 Price Target and New 'Outperform' Rating From Leerink Partners (NASDAQ: ENTX) - Benzinga
Entera Bio Stock Price Forecast. Should You Buy ENTX? - StockInvest.us
Entera Bio Ltd. WarrantADR (ENTXW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Entera Bio Ltd. SEC Filing (Aug 31, 2026) - Stock Titan
ENTX Q2 2026 Earnings: Wider-than-Expected Loss of -$0.14 Per Share on Zero RevenueRevenue Guidance Update - careplusvn.com
Entera to Participate in Upcoming Fall Investor Conferences - Yahoo Finance
Entera (ENTX) Earnings Reading: Reported EPS Misses Expectations on the Day; Stock Move: Shares Move Higher 5.88%Quarterly Profit Report - vinanet.vn
Entera Bio (NASDAQ:ENTX) Stock Price Up 5.1%Here's Why - MarketBeat
Entera Bio CEO Miranda Toledano to speak at Canaccord Genuity conference - scanx.trade
Entera (ENTX) Earnings Snapshot: Profit Per Share Falls Below Its Benchmark in the Reported Period - vinanet.vn
Entera (ENTX) Results Review: EPS Misses Its Estimate; Market Move: Shares Finish 4.84% Up in the Current Update - vinanet.vn
Entera Bio appoints new chief medical officer - The Globe and Mail
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Entera Bio appoints Riccardo Camisasca as chief medical officer - Investing.com
Entera Bio Names New Chief Medical Officer Ahead of EB613 Phase 3 Start - Minichart
Form 8K Entera Bio Ltd. For: 18 August By Investing.com - Investing.com India
Entera Bio appoints Riccardo Camisasca as chief medical officer By Investing.com - Investing.com Canada
A drug developer with 30-plus years joins Entera for a planned osteoporosis Phase 3 trial - Stock Titan
Renaissance Technologies LLC Buys 365,441 Shares of Entera Bio Ltd. $ENTX - MarketBeat
ENTX Q2 2026 Earnings: EPS Miss of 71.6% and Zero Revenue – Shares Move HigherEPS Growth Report - dars.gov.et
ENTX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Pipeline InvestmentEPS Guidance Update - careplusvn.com
Entera Bio Ltd (ENTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement - MarketBeat
Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Increases By 286.7% - MarketBeat
ENTX Q2 2026 Earnings: Wider-Than-Expected Loss per Share Reflects Clinical-Stage InvestmentGeographic Revenue Trends - careplusvn.com
Entera Bio at Canaccord Genuity: oral osteoporosis push advances By Investing.com - Investing.com Canada
Entera Bio (ENTX) completes $275M Rule 506(b) private offering of shares and warrants - Stock Titan
Entera Bio at Canaccord Genuity: oral osteoporosis push advances - Investing.com
Entera Bio shares slip as Q2 loss comes in wider than expected - Yahoo Finance
Entera Bio misses Q2 estimates, reports wider loss By Investing.com - Investing.com Nigeria
Entera Bio misses Q2 estimates, reports wider loss - Investing.com
Entera Bio Ltd. (ENTX) stock price, news, quote and history - au.finance.yahoo.com
Entera Bio (NASDAQ:ENTX) Upgraded to Sell at Wall Street Zen - MarketBeat
Entera Bio raises $275M in oversubscribed placement, shares rebound on funding news - scanx.trade
Entera Bio (NASDAQ:ENTX) Announces Earnings Results - MarketBeat
Entera Bio Q2 EPS misses estimate as net loss widens to $7.3 million - scanx.trade
Entera Bio Strengthens Finances to Advance Oral Peptide Pipeline - TipRanks
Entera Announces Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Entera Bio Reports Q2 2026 Loss and $275 Million Private Placement - Moomoo
Entera Bio Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Entera Bio (ENTX) awards 180,000 options to Chief of R&D - Stock Titan
Entera Q2 2026 earnings: Phase 3 preparation widened the loss - TradingKey
ENTX: FDA-aligned Phase 3 for EB613 and $275M financing secure pipeline progress and cash runway - TradingView
Entera Bio Ltd. Q2 2026: Revenue $0M, Net loss $7.31M, EPS ($0.14) — 10-Q Summary - TradingView
3.06%
2.55%
자본화:
|
볼륨(24시간):